Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-19401-3, published online 02 September 2022
The Acknowledgments section in the original version of this Article was omitted. The Acknowledgments section now reads:
“This work is partially funded by NIH the National Center for Advancing Translational Sciences (NCATS) UCLACTSI (UL1 TR001881-01), NCI grant P01CA233452-02, and U01 grantCA232859-01.”
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gong, J., Thomassian, S., Kim, S. et al. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep 12, 18731 (2022). https://doi.org/10.1038/s41598-022-23619-6
Published:
DOI: https://doi.org/10.1038/s41598-022-23619-6
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
